Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNX-5422 + ibrutinib
- Development stage
- Discontinued
- Lead developer
- Esanex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SNX-5422 + ibrutinib is a combination therapy under investigation primarily for the treatment of chronic lymphocytic leukemia (CLL), especially in patients who have developed resistance to ibrutinib. SNX-5422 is an orally active, synthetic small molecule inhibitor of heat shock protein 90 (Hsp90). It acts as a prodrug for SNX-2112 and leads to degradation of Hsp90 client proteins such as HER2, AKT, and ERK. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that targets B-cell receptor signaling in CLL. The combination has shown preclinical efficacy in models resistant to BTK inhibition by promoting survival benefit and reducing tumor burden compared to either agent alone. Clinical trials are ongoing to evaluate safety and efficacy in CLL patients with residual disease on ibrutinib monotherapy[1][3][4][5][6].
- Other names
- SNX 5422SNX5422SNX-5422
02
Targets
BTK (Bruton tyrosine kinase)HSP90B1 (GRP94)HSP90AA1 (Heat shock protein HSP90-alpha)HSP90AB1 (Heat shock protein HSP 90-beta)TRAP1 (Tumor necrosis factor receptor-associated protein 1)
Beyond the preview
Go deeper on SNX-5422 + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNX-5422 + ibrutinib.